# Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)

> **NCT01498419** · PHASE2 · COMPLETED · sponsor: **Global Alliance for TB Drug Development** · enrollment: 207 (actual)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **DRUG:** Moxifloxacin (M)
- **DRUG:** Pretomid (Pa)
- **DRUG:** Pyrazinamide (Z)
- **DRUG:** Rifafour

## Key facts

- **NCT ID:** NCT01498419
- **Lead sponsor:** Global Alliance for TB Drug Development
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-04
- **Final completion:** 2013-07
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2018-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01498419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01498419, "Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01498419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*